iXCells Forms Collaboration To Evaluate Chemotherapy Toxicity
iXCells Biotechnologies on March 25, 2026 announced an international collaboration with Rosebud Biosciences, Kantify, and Incite to evaluate off‑target chemotherapeutic toxicities using patient‑specific organoids. The partners will reprogram a liposarcoma patient's PBMCs into hiPSCs, generate heart, liver, and kidney organoids, and apply Kantify's investigational compounds with longitudinal imaging and machine‑learning analyses to produce personalized multi‑organ toxicity profiles informing therapy decisions.
Key Points
- 1Reprograms patient PBMCs into hiPSCs and creates heart, liver, kidney organoids for toxicity testing
- 2Targets off‑target organ toxicity—major cause of clinical trial failures in oncology drug development
- 3Generates personalized multi‑organ toxicity profiles using imaging and ML to guide therapy decisions
Scoring Rationale
Official cross‑company collaboration with experimental patient‑derived organoids drives translational relevance; limited novelty and narrow, pilot-scale scope.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
